<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mometasone (nasal): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mometasone (nasal): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mometasone (nasal): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12255" href="/d/html/12255.html" rel="external">see "Mometasone (nasal): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16021" href="/d/html/16021.html" rel="external">see "Mometasone (nasal): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8775137"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nasonex [DSC];</li>
<li>Propel;</li>
<li>Propel Mini SDS;</li>
<li>Sinuva</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869273"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Mometasone;</li>
<li>Mosaspray [DSC];</li>
<li>Nasonex;</li>
<li>SANDOZ Mometasone;</li>
<li>TEVA-Mometasone</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8775147"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Nasal</li></ul></div>
<div class="block doa drugH1Div" id="F8775312"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For patients with mucous crusting, rinsing with saline nasal spray before mometasone administration can remove mucous crusting and improve nasal coating (deShazo 2021). If nasal obstruction is so severe that sprays cannot penetrate when treating rhinitis, consider concomitant use of an intranasal decongestant for up to 5 days (Dykewicz 2020).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bbb7ccf-d15a-498e-8e6f-2d380afc56c3">Allergic rhinitis, seasonal, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, seasonal, prophylaxis: Intranasal:</b> 2 sprays (100 mcg) in each nostril once daily (total daily dose: 200 mcg); treatment should begin 2 to 4 weeks prior to the anticipated start of pollen season.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef40a39c-9ea3-4ff6-810a-a525dd53d280">Nasal polyps</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal polyps:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal:</b> 2 sprays (100 mcg) in each nostril twice daily (total daily dose: 400 mcg); 2 sprays (100 mcg) in each nostril once daily may be effective in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Implant:</b> 1 implant (1,350 mcg) placed in the ethmoid sinus under endoscopic visualization for up to 90 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonallergic rhinitis (off-label use): Intranasal:</b> 2 sprays (100 mcg) in each nostril once daily (total daily dose: 200 mcg) (Lieberman 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed2f11f3-66bd-41a2-ade9-f0a7121748d6">Rhinosinusitis, adjunctive treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, adjunctive treatment (acute) (off-label use):</b>
<b>Intranasal:</b> Intranasal corticosteroids such as mometasone are recommended by Infectious Diseases Society of America (IDSA) and American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNS) guidelines but no specific dosing recommendations are made. The following dosing recommendations have been made: 2 sprays (100 mcg) in each nostril twice daily (total daily dose: 400 mcg); if inadequate symptom control, may increase to 4 sprays (200 mcg) in each nostril twice daily (total daily dose: 800 mcg) (Nasonex Canadian product labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99e6d7cb-82d2-459d-a28d-ef4733dc10bf">Rhinosinusitis, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, </b>
<b>chronic </b>
<b>(off-label use): Intranasal:</b> 2 sprays (100 mcg) in each nostril once or twice daily (total daily dose: 200 to 400 mcg) for 3 to 6 months (Chong 2016; Holbrook 2020; Huang 2013; MÃ¶sges 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d622a1cb-b9ab-4c3d-884a-e42a4d056a29">Rhinosinusitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, treatment (acute, mild to moderate, uncomplicated) (off-label use):</b>
<b>Intranasal:</b> 2 sprays (100 mcg) in each nostril twice daily (total daily dose: 400 mcg); up to 15 days of treatment was studied (Meltzer 2005).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f19228ca-0b9f-4938-821a-f482214139a6">Upper respiratory allergies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper respiratory allergies (OTC):</b>
<b>Intranasal:</b> 2 sprays (100 mcg) in each nostril once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990336"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied)</p></div>
<div class="block doha drugH1Div" id="F50987689"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; drug accumulation may increase with severity of hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F8775313"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8775311"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16021" href="/d/html/16021.html" rel="external">see "Mometasone (nasal): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed30d02d-dd05-494e-bc5b-0d0387493686">Allergic rhinitis, perennial or seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial (relief of nasal symptoms) or seasonal (relief of nasal symptoms and congestion):</b> Intranasal: Spray (50 mcg/spray):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention</i>
<i>:</i> Children â¥12 years and Adolescents: 100 mcg (2 sprays) <b>per nostril</b> once daily (total daily dose: 200 mcg/day) beginning 2 to 4 weeks prior to pollen season</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 11 years: 50 mcg (1 spray) <b>per nostril</b> once daily (total daily dose: 100 mcg/day)</p>
<p style="text-indent:-2em;margin-left:6em;">Children â¥12 years and Adolescents: 100 mcg (2 sprays) <b>per nostril</b> once daily (total daily dose: 200 mcg/day)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="baa64232-71eb-4ed2-b997-b86ca190c67b">Nasal airway obstruction/adenoidal hypertrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal airway obstruction/adenoidal hypertrophy: </b>Limited data available: Children and Adolescents 3 to 15 years: Intranasal: Spray: Initial: 50 mcg (1 spray) <b>per nostril</b> once daily (total daily dose: 100 mcg/day) for 6 weeks, followed by the same dose given every 24 hours for the first 2 weeks of each month. Dosing based on two studies: The first was a randomized, placebo-controlled study (n=122; treatment arm: 67; age range; 3 to 15 years) in which patients received therapy for 6 weeks and 67.2% had a significant decrease in adenoid size compared to the control group (p&lt;0.001) (Cengel 2006). The second was a 2-stage, placebo-controlled, randomized study (n=60, treatment arm: 30; age range: 3 to 7 years) which showed that after 40 days of daily mometasone therapy, ~77.7% of patients were considered responders and able to avoid adenoidectomy; those who responded continued therapy every 24 or 48 hours for the first 2 weeks of three subsequent months (Berlucchi 2007). Long-term analysis of children receiving the daily dose for the first 2 weeks of each month continued to show improvement after a mean followup period of 28 months and the need for surgery remained reduced (Berlucchi 2008). A meta-analysis of eight randomized trials supported significant decrease in adenoid size and improvement in otitis media with effusion in this population (Chohan 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f9d6c461-1e30-47a6-ae59-1103167b6d8c">Nasal polyps, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal polyps, treatment:</b> Adolescents â¥18 years: Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Implant: 1 implant (1,350 mcg) placed in the ethmoid sinus under endoscopic visualization for up to 90 days</p>
<p style="text-indent:-2em;margin-left:4em;">Spray: 100 mcg (2 sprays) <b>per nostril</b> twice daily (total daily dose: 400 mcg/day); a lower dose of 200 mcg once daily delivered as 100 mcg (2 sprays) <b>per nostril</b> once daily may be effective in some patients</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130317"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51130318"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Mometasone concentrations appear to increase with the severity of hepatic impairment; use with caution.</p></div>
<div class="block adr drugH1Div" id="F8775194"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Nasal spray adverse reactions reported in adolescents and adults; implant adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection (nasal spray: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (nasal spray: 26%; implant: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Blood in nasal mucosa (nasal spray: â¤11%), epistaxis (nasal spray: â¤13%; implant: 2%), pharyngitis (nasal spray: 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (nasal spray: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (nasal spray: 2% to 5%), dyspepsia (nasal spray: 2% to 5%), nausea (nasal spray: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (nasal spray: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (implant: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (nasal spray: 2% to 5%), musculoskeletal pain (nasal spray: 5%), myalgia (nasal spray: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (nasal spray: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (nasal spray: 2% to 5%), otitis media (implant: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (nasal spray and implant: 2% to 5%), bronchitis (nasal spray and implant: 2% to 5%), cough (nasal spray: 7%), flu-like symptoms (nasal spray: 2% to 5%), nasopharyngitis (implant: 1%), upper respiratory tract infection (nasal spray and implant: 6% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all formulations):</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal candidiasis, nasal mucosa ulcer, pharyngeal candidiasis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all formulations):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of the nose</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal cavity pain, nasal mucosa irritation, nasal septum perforation</p></div>
<div class="block coi drugH1Div" id="F8775191"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mometasone or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use to treat asthma, if nose injury or surgery is not fully healed, or in children &lt;2 years of age.</p></div>
<div class="block war drugH1Div" id="F8775192"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Adrenal suppression: When recommended doses are exceeded, or in extremely sensitive individuals, may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis. Reports consistent with hypercortisolism are rare. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Hypersensitivity reactions: Hypersensitivity reactions, including rash, pruritus, angioedema, and wheezing, have been reported; discontinue if such reactions occur.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid exposure to chickenpox and/or measles, especially if not immunized.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Local nasal effects: Nasal septum perforation, epistaxis, irritation, and infection of the nose and/or pharynx may occur. Periodically examine nasal mucosa; discontinuation of therapy may be necessary if an infection occurs. Avoid use of nasal implant in patients with nasal ulcers or trauma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Hepatic impairment: Use with caution in patients with hepatic impairment: drug accumulation may increase with severity of hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Infections: Use with caution or avoid use in patients with tuberculosis (TB) disease (active TB) or infection (latent TB) of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Do not use in untreated localized infection involving the nasal mucosa; concurrent antimicrobial therapy should be administered if bacterial infection of the sinuses is suspected/confirmed.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users or in patients who report visual changes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Appropriate use: Implant: For patients who have had ethmoid sinus surgery; insertion by health care providers trained in otolaryngology only. There are no studies evaluating repeat implantation of the implant.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Appropriate use: Spray: Prior to use, the dose and duration of treatment should be based on the risk vs benefit for each individual patient. In general, use the smallest effective dose for the shortest duration of time to minimize adverse events. A gradual tapering of dose may be required prior to discontinuing therapy. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing inhalation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">â¢ Self-medication (OTC use): Consult a health care provider before use if you have an eye infection; have or had glaucoma or cataracts; are using medicine for HIV infection (eg, ritonavir); are using a steroid for asthma, allergies, or skin rash; or are using ketoconazole. Discontinue use and consult a health care provider if symptoms do not improve after 1 week or new symptoms occur (eg, facial pain, thick nasal discharge); you have or come in contact with someone who has chickenpox, measles, or tuberculosis; a constant whistling sound occurs from the nose; allergic reaction occurs; changes in vision; or severe or frequent nosebleeds occur.</p></div>
<div class="block dosfc drugH1Div" id="F21005930"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Nasonex 17 g bottles contain 120 sprays.</p></div>
<div class="block foc drugH1Div" id="F8775337"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Nasal, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Propel: 370 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Propel Mini SDS: 370 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sinuva: 1350 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasonex: 50 mcg/actuation (17 g [DSC]) [contains benzalkonium chloride, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/actuation (17 g)</p></div>
<div class="block geq drugH1Div" id="F8775140"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8775339"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Propel Mini Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">370 mcg (per each): $1,860.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Propel Mini SDS Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">370 mcg (per each): $1,860.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Propel Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">370 mcg (per each): $1,860.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Sinuva Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1350 mcg (per each): $1,769.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Mometasone Furoate Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/ACT (per gram): $15.07 - $15.70</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869274"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasonex: 50 mcg/actuation (1 ea) [contains benzalkonium chloride, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/actuation (1 ea, 17 g)</p></div>
<div class="block adm drugH1Div" id="F8775315"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Spray:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC:</i> For intranasal administration only; do not spray into eyes or mouth. Shake bottle well. Prime pump (press 10 times or until fine spray appears) prior to first use, bottle has not been used in 1 week, or nozzle has just been cleaned; if mist does not appear after 10 pumps, nozzle may be clogged. Blow nose to clear nostrils. Close one nostril and insert tip of spray nozzle in the other nostril aiming slightly away from the center of the nose. While sniffing, press spray nozzle to release dose; exhale through mouth. After each use, wipe the spray tip with a clean tissue and replace cap. Clean spray nozzle weekly or when clogged; do not try to unblock clogs with a pin or sharp object. To clean, remove spray nozzle and rinse under running tap water; dry at room temperature. Clogged nozzles may be soaked in warm water prior to running under tap water.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rx:</i> For intranasal administration only. Prime pump (press 10 times or until fine spray appears) prior to first use. If 7 or more days have elapsed since last use, reprime pump with 2 sprays or until a fine mist appears. Shake before using. Blow nose to clear nostrils. Insert applicator into nostril, tilt head slightly forward keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray; exhale through mouth. After each use, wipe the spray tip with a clean tissue and replace cap. Avoid spraying directly into nasal septum, eyes or mouth. Discard after 120 medicated sprays have been used, even if bottle is not completely empty.</p>
<p style="text-indent:-2em;margin-left:2em;">Implant: Place in the ethmoid sinus under endoscopic visualization; avoid bending, twisting, or damaging implant; do not compress or load implant into the delivery system more than 2 times. Refer to manufacturer's product labeling for complete preparation, administration, and removal information.</p></div>
<div class="block admp drugH1Div" id="F52614379"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Intranasal:</p>
<p style="text-indent:-2em;margin-left:2em;">Implant: Place in the ethmoid sinus under endoscopic visualization; avoid bending, twisting, or damaging implant; do not compress or load implant into the delivery system more than 2 times. Refer to manufacturer's product labeling for complete preparation, administration, and removal information.</p>
<p style="text-indent:-2em;margin-left:2em;">Spray: Shake well prior to each use. Before first use, prime by pressing pump 10 times or until a fine spray appears. Repeat priming with 2 sprays or until a fine spray appears if â¥1 week between use. Blow nose to clear nostrils before each use. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Do not spray into eyes or mouth. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p>
<p style="text-indent:-2em;margin-left:4em;">After removing nasal spray from container, avoid prolonged exposure of product to direct light; brief exposure to light (with normal use) is acceptable.</p></div>
<div class="block meg drugH1Div" id="F51672522"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Nasonex: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F020762s053lbl.pdf%23page%3D11&amp;token=JoGOxYNaaQRp4G%2B0V6oGmQdjqbeRNmGr6XqWPKKpYX7FXLxEzaW%2F9VqFAxREJY1xJk%2BAOOLPxld3F9NKAhvCRte2XoaHmgcoPtx6cO8DO%2F9Vmz74VuTV5DLzNvPft8j7&amp;TOPIC_ID=9778" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020762s053lbl.pdf#page=11</a></p></div>
<div class="block use drugH1Div" id="F8775185"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal polyps:</b> Treatment of chronic rhinosinusitis with nasal polyps in patients â¥18 years. <b>Note:</b> Implant is for patients who have had ethmoid sinus surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seasonal allergic rhinitis (prophylaxis) (Rx spray only): </b> Prophylaxis of nasal symptoms of seasonal allergic rhinitis in adults and pediatric patients â¥12 years.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper respiratory allergies (OTC products):</b> Relief of hay fever and other upper respiratory allergies (eg, nasal congestion, runny nose, sneezing, itchy nose) in adults and children â¥2 years of age.</p></div>
<div class="block off-label drugH1Div" id="F25469202"><span class="drugH1">Use: Off-Label: Adult</span><p>Chronic rhinosinusitis; Nonallergic rhinitis; Rhinosinusitis, adjunctive treatment (acute); Rhinosinusitis, treatment (acute, mild to moderate, uncomplicated)</p></div>
<div class="block cyt drugH1Div" id="F8775199"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8775200"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within âCYP3A4 Inducers [Strong]â are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the âLaunch drug interactions programâ link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Mometasone (Nasal).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Corticosteroids (Nasal) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal corticosteroid on an esketamine dosing day should administer the nasal corticosteroid at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Nasal).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F8775187"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Maternal use of intranasal corticosteroids in usual doses are not associated with an increased risk of fetal malformations or preterm birth (ERS/TSANZ [Middleton 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Although intranasal mometasone has limited systemic absorption and use in pregnancy is likely acceptable, other agents have more pregnancy data and may be preferred for the treatment of allergic rhinitis in pregnant women (Alhussien 2018; BSACI [Scadding 2017]; ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block brc drugH1Div" id="F8775190"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if mometasone is present in breast milk following nasal inhalation; however, systemic absorption is low (&lt;1%).</p>
<p style="text-indent:0em;margin-top:2em;">Systemic corticosteroids are present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Intranasal mometasone is considered compatible with breastfeeding (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block mop drugH1Div" id="F45626063"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency; glaucoma and/or cataracts, especially in patients with a change in vision; adverse nasal effects (eg, nasal septal perforation, nasal ulceration, irritation, epistaxis, infection).</p></div>
<div class="block pha drugH1Div" id="F8775226"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Leukocytes and macrophages may have to be present for the initiation of responses mediated by the above substances. Inhibits the margination and subsequent cell migration to the area of injury, and also reverses the dilatation and increased vessel permeability in the area resulting in decreased access of cells to the sites of injury.</p></div>
<div class="block phk drugH1Div" id="F8775228"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Spray: Improvement in allergic rhinitis symptoms may be seen within 11 hours; Maximum effect: Within 1 to 2 weeks after starting therapy</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Implant: â¤90 days</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Undetectable in plasma; clinical effects are due to direct local effect, rather than systemic absorption</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: V<sub>d</sub>: 152 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98% to 99%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; extensive via CYP3A4 to multiple metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Spray: &lt;1%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: ~5 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Bile (primary route): urine (limited)</p></div>
<div class="block phksp drugH1Div" id="F51159691"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Concentrations may increase with severity of hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961990"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nasonex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nasonex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nasonex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Nasonex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Garmisch rinosal | Momeskyn | Rinaid | Rinobudex</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Metmin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Trinaria</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Rinetason</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sniffacan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Mometazonfuroat cipla | Nasonex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Metmin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Momeflo | Mozapt</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zhekort</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Topcort</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Boryung mometasone | Monitazone | Mononex | Nazacare | Neselex | Nometasone | Nose top</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Breso</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Conasal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Coliflem</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Monitazone</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pharmacy health mometasone allergy relief</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Metmin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sinuva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bonair m</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Alivio | Momate | Mometix AQ | Nasonex Aqueous | Sinocort | Tabunex Spray</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Nasonex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aphiahsone | Nasonex | Nasonex novum</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mometasone sandoz</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nazoster</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Zentason</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Nasonex aqueous</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Nasonex aqueous</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29164323">
<a name="29164323"></a>Alhussien AH, Alhedaithy RA, Alsaleh SA. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. <i>Eur Arch Otorhinolaryngol</i>. 2018;275(2):325â333. doi:10.1007/s00405-017-4785-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/29164323/pubmed" id="29164323" target="_blank">29164323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17533178">
<a name="17533178"></a>Berlucchi M, Salsi D, Valetti L, et al. The Role of Mometasone Furoate Aqueous Nasal Spray in the Treatment of Adenoidal Hypertrophy in the Pediatric Age Group: Preliminary Results of a Prospective, Randomized Study. <i>Pediatrics</i>. 2007;119(6):e1392-e1397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/17533178/pubmed" id="17533178" target="_blank">17533178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18499270">
<a name="18499270"></a>Berlucchi M, Valetti L, Parrinello G, et al. Long-Term Follow-Up of Children Undergoing Topical Intranasal Steroid Therapy For Adenoidal Hypertrophy.<i> Int J Pediatr Otorhinolaryngol</i>. 2008;72(8):1171-1175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/18499270/pubmed" id="18499270" target="_blank">18499270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16169093">
<a name="16169093"></a>Cengel S, Akyol MU. The Role of Topical Nasal Steroids in the Treatment of Children With Otitis Media With Effusion and/or Adenoid Hypertrophy. <i>Int J Pediatr Otorhinolaryngol</i>. 2006;70(4):639-645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/16169093/pubmed" id="16169093" target="_blank">16169093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nasonex.4">
<a name="Nasonex.4"></a>Children's Nasonex 24HR Allergy (mometasone) [prescribing information]. Allegan, MI: Perrigo; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27115215">
<a name="27115215"></a>Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis. <i>Cochrane Database Syst Rev</i>. 2016;4:CD011993. doi:10.1002/14651858.CD011993.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/27115215/pubmed" id="27115215" target="_blank">27115215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26235732">
<a name="26235732"></a>Chohan A, Lal A, Chohan K, Chakravarti A, Gomber S. Systematic review and meta-analysis of randomized controlled trials on the role of mometasone in adenoid hypertrophy in children. <i>Int J Pediatr Otorhinolaryngol</i>. 2015;79(10):1599-1608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/26235732/pubmed" id="26235732" target="_blank">26235732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-deShazo.1">
<a name="deShazo.1"></a>deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol.</i> 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26012297">
<a name="26012297"></a>Guo L, Sun X, Yang J, Liu J, Wang D. Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis [article in Chinese].<i> Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</i>. 2015;29(3):243-245, 251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/26012297/pubmed" id="26012297" target="_blank">26012297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pilewski.2018">
<a name="Pilewski.2018"></a>Holbrook EH. Chronic rhinosinusitis: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23277167">
<a name="23277167"></a>Huang A, Govindaraj S. Topical therapy in the management of chronic rhinosinusitis. <i>Curr Opin Otolaryngol Head Neck Surg</i>. 2013;21(1):31-38. doi:10.1097/MOO.0b013e32835bc4ab<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/23277167/pubmed" id="23277167" target="_blank">23277167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26800862">
<a name="26800862"></a>Lal D, Jategaonkar AA, Borish L, et al. Management of rhinosinusitis during pregnancy: systematic review and expert panel recommendations. <i>Rhinology</i>. 2016;54(2):99-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/26800862/pubmed" id="26800862" target="_blank">26800862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lieberman.1">
<a name="Lieberman.1"></a>Lieberman PL. Chronic nonallergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926173">
<a name="22926173"></a>Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. <i>Pediatrics</i>. 2012;130(3):576-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/22926173/pubmed" id="22926173" target="_blank">22926173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16337461">
<a name="16337461"></a>Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. <i>J Allergy Clin Immunol.</i> 2005;116(6):1289-1295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/16337461/pubmed" id="16337461" target="_blank">16337461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mosaspray.1">
<a name="Mosaspray.1"></a>Mosaspray (mometasone) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21318604">
<a name="21318604"></a>MÃ¶sges R, Bachert C, Rudack C, et al. Efficacy and safety of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis. <i>Adv Ther</i>. 2011;28(3):238-249. doi:10.1007/s12325-010-0105-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/21318604/pubmed" id="21318604" target="_blank">21318604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27012010">
<a name="27012010"></a>Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/27012010/pubmed" id="27012010" target="_blank">27012010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nasonex.5">
<a name="Nasonex.5"></a>Nasonex 24HR Allergy (mometasone) [prescribing information]. Allegan, MI: Perrigo; received March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nasonex.1">
<a name="Nasonex.1"></a>Nasonex (mometasone intranasal) [prescribing information]. Jersey City, NJ: Organon LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nasonex.2">
<a name="Nasonex.2"></a>Nasonex (mometasone intranasal) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nasonex.3">
<a name="Nasonex.3"></a>Nasonex (mometasone intranasal) [product information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27141307">
<a name="27141307"></a>Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. <i>Multidiscip Respir Med</i>. 2016;11:18. doi:10.1186/s40248-016-0054-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/27141307/pubmed" id="27141307" target="_blank">27141307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24654314">
<a name="24654314"></a>Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. <i>J Investig Allergol Clin Immunol</i>. 2013;23(7):495-503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/24654314/pubmed" id="24654314" target="_blank">24654314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856â889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sinuva.1">
<a name="Sinuva.1"></a>Sinuva (mometasone) [prescribing information]. Menlo Park, CA: Intersect ENT; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29438602">
<a name="29438602"></a>Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. <i>Int Forum Allergy Rhinol</i>. 2018;8(2):108-352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-nasal-drug-information/abstract-text/29438602/pubmed" id="29438602" target="_blank">29438602</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9778 Version 244.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
